^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | LB-100 (PP2A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer
Published date:
05/16/2018
Excerpt:
This pre-clinical study demonstrates that LB-100 is effective against cell lines with acquired lapatinib resistance, which may translate into clinical efficacy in lapatinib resistant HER2-positive BC.
